Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio

Chronic inflammatory mediators enhance prostate cancer development and progression

(2015) Dinesh Thapa et al.   BIOCHEMICAL PHARMACOLOGY

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies

(2015) E. David Crawford et al.   JOURNAL OF UROLOGY

Sequencing of agents in castration-resistant prostate cancer

(2015) David Lorente et al.   LANCET ONCOLOGY

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

(2014) R. Leibowitz-Amit et al.   ANNALS OF ONCOLOGY

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†

(2014) R. J. van Soest et al.   ANNALS OF ONCOLOGY

Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio

(2014) Arnoud J. Templeton et al.   CANCER

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequential Treatment with Taxanes and Novel Anti-Androgenic Compounds in Castration-Resistant Prostate Cancer

(2014) Lukas Esch et al.   Oncology Research and Treatment

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

(2013) Y. Loriot et al.   ANNALS OF ONCOLOGY

Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel

(2013) Philipp Nuhn et al.   BJU INTERNATIONAL

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram

(2012) D. Keizman et al.   ONCOLOGIST

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone

(2011) Eleni Efstathiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection

(2010) Farhan Rashid et al.   World Journal of Surgical Oncology

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY